The STAMPEDE trial employs a gene expression test to enhance outcomes in advanced prostate cancer, analyzing over 12,000 participants since 2005. Led by University College London and Cancer Research UK, it merges clinical data with genomic insights, highlighting distinct tumor behaviors missed by standard evaluations. Notably, higher genomic risk scores correspond to patient outcomes, emphasizing the utility of genomic classifiers in guiding chemotherapy decisions. This innovative approach aims to refine treatment options and bolster personalized patient care in oncology.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.